Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes

Autor: the iDCL Trial Research Group, Roy W. Beck, Daniel Cherñavvsky, Betsy B. Dokken, Craig Kollman, Mary Oliveri, Bruce A. Buckingham, Mark D. DeBoer, Stuart A. Weinzimer, Liana J. Hsu, Emma Emory, Lori Carria, Emily Jost, Melissa J. Schoelwer, Eda Cengiz, Gregory P. Forlenza, Laya Ekhlaspour, Katrina J. Ruedy, Marc D. Breton, R. Paul Wadwa, Lauren G. Kanapka
Rok vydání: 2020
DOI: 10.2337/figshare.13260212.v1
Popis: Objective: To further evaluate the safety and efficacy of the Control-IQ closed loop control (CLC) system in children with type 1 diabetes. Research Design and Methods: Following a 16-week randomized clinical trial (RCT) comparing CLC with sensor augmented pump (SAP) therapy in 101 children age 6 to 13 years old with type 1 diabetes, 22 participants in the SAP group initiated use of the CLC system (referred to as SAP-CLC cohort), and 78 participants in the CLC group continued use of CLC (CLC-CLC cohort) for 12 weeks. Results: In the SAP-CLC cohort, mean percentage of time in range 70-180 mg/dL (TIR) increased from 55±13% using SAP during the RCT to 65±10% using CLC (P70% plus time Conclusions: This further evaluation of the Control-IQ CLC system supports the findings of the preceding RCT that use of a closed-loop system can safely improve glycemic control in children 6 to 13 years old with type 1 diabetes from the first day of use and demonstrates that these improvements can be sustained through 28 weeks of use.
Databáze: OpenAIRE